Ilirjana Bajrami

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

Yuqiao Shen, Farah Rehman, Ying Feng et al. · Clinical Cancer Research · 2013 · 487 citations · Full text

Medicine, Oncology, Pharmacology +14

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity

Ilirjana Bajrami, Jessica Frankum, Asha Konde et al. · Cancer Research · 2013 · 368 citations · Full text

Medicine, Oncology, Pharmacology +17

PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer

Roman M. Chabanon, Gareth Muirhead, Dragomir B. Krastev et al. · Journal of Clinical Investigation · 2018 · 324 citations · Full text

Life Sciences, Immunology, Oncology +17

Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

Lynn Bjerke, Alan Mackay, Meera Nandhabalan et al. · Cancer Discovery · 2013 · 315 citations · Full text

Medicine, Genetics, Oncology +17

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer

Elise Ruark, Katie Snape, Peter Humburg et al. · Nature · 2012 · 257 citations · Full text

Medicine, Genetics, Oncology +14